Skip to main content

Table 2 Mild cognitive impairment participant overview

From: Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease

 

Total MCI

sMCI

cMCI

Urine

   

 Participants

209

167

42

 Male/female

95/114

80/87

15/27

 Mean age (SD)

76.33 (6.03)

76.17 (5.60)

76.91 (7.38)

 MMSE

26.86 (2.75)

26.93 (2.94)

26.55 (1.76)

 CDR

0.49 (0.08)

0.48 (0.09)

0.51 (0.08)

 Reported SSRI medication

16

12

4

Serum

   

 Participants

165

90

75

 Male/female

71/94

42/48

29/46

 Mean age

77.50 (6.49)

75.98 (5.95)

79.32 (6.67)

 MMSE

26.73 (2.24)

26.81 (2.38)

26.63 (2.07)

 CDR

0.49 (0.11)

0.48 (0.10)

0.53 (0.12)

 Reported SSRI medication

11

8

3

  1. Overview of the two MCI subgroups used in the study. All samples in the study were taken at baseline; however, one MCI subgroup remained stable throughout follow-up visits (sMCI), whilst the second converted to a clinical diagnosis of AD at subsequent follow-up visits (cMCI). SSRI selective serotonin reuptake inhibitor, MMSE Mini-Mental State Examination score, CDR Clinical Dementia Rating